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Abstract
Background Chronic rhinosinusitis (CRS) is a hetero-
geneous, multifactorial inflammatory disease of the
nasal and paranasal mucosa. It has not been possi-
ble to date to develop an internationally standardized,
uniform classification for this disorder. A phenotype
classification according to CRS with (CRSwNP) and
without polyposis (CRSsNP) is usually made. How-
ever, a large number of studies have shown that there
are also different endotypes of CRS within these phe-
notypes, with different pathophysiologies of chronic
inflammation of the nasal mucosa. This review de-
scribes the central immunological processes in nasal
polyps, as well as the impact of related diseases on
the inflammatory profile of nasal polyps.
Materials andmethods The current knowledge on the
immunological and molecular processes of CRS, in
particular CRSwNP and its classification into specific
endotypes, was put together by means of a struc-
tured literature search in Medline, PubMed, the na-
tional and international guideline registers, and the
Cochrane Library.
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Results Based on the current literature, the differ-
ent immunological processes in CRS and nasal polyps
were elaborated and a graphical representation in the
form of an immunological network developed. In ad-
dition, different inflammatory profiles can be found
in CRSwNP depending on related diseases, such as
bronchial asthma, cystic fibrosis (CF), or NASID-Ex-
acerbated Respiratory Disease (N-ERD).
Conclusion The identification of different endotypes
of CRSwNP may help to improve diagnostics and
develop novel individual treatment approaches in
CRSwNP.
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Abbreviations
AFRS Allergic fungal rhinosinusitis
AIS Aspirin-intolerance syndrome
AFS Allergic fungal sinusitis
AScA Asthmatic sinusitis with allergy
ASsA Asthmatic sinusitis without allergy
BCA B cell-attracting chemokine
CD Cluster of differentiation
CF Cystic fibrosis
CFTR Cystic fibrosis transmembrane conduc-
tance regulator protein
CRS Chronic rhinosinusitis
CRSsNP Chronic rhinosinusitis without nasal
polyps
CRSwNP Chronic rhinosinusitis with nasal polyps
CCL CC motif chemokine ligand
CCR CC motif chemokine receptor
CXCL CXC motif chemokine ligand
CXCR CXC motif chemokine receptor
ECP Eosinophilic cationic protein
EFRS Eosinophilic fungal rhinosinusitis
IgA Immunoglobulin A
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IgE Immunoglobulin E
IFN Interferon
IL Interleukin
ILC Innate lymphoid cells
MPO Myeloperoxidase
NAScA Non-asthmatic sinusitis with allergy
N-ERD NASID-exacerbated respiratory disease
SDF Stromal cell-derived factor
TFH Follicular helper T cells
Th T helper
TNF Tumor necrosis factor
TNSS Total nasal symptom score
TSLP Thymic stromal lymphopoietin
Introduction
Chronic rhinosinusitis (CRS) affects approximately
5–15% of the European and American population,
making it a widespread health problem that cre-
ates significant costs for health systems and national
economies [1, 2]. Clinically, CRS (with or without
nasal polyps) in adults is defined as the presence of
two or more symptoms one of which should be ei-
ther nasal blockage/obstruction/congestion or nasal
discharge (anterior/posterior nasal drip), ± reduc-
tion or loss of smell, ± facial pain/pressure, for more
than 12 weeks [1, 3]. Secondary symptoms such as
headache, fever, halitosis, cough, toothache, drowsi-
ness, or ear pressure may also be present. More
recent US and European guidelines require—in ad-
dition to two main criteria—endoscopic and/or ra-
diological evidence of inflammatory tissue [1, 4].
Based on endoscopic examinations of the nasal cav-
ity or imaging procedures, CRS can be differenti-
ated into chronic rhinosinusitis with nasal polyps
(CRSwNP) and chronic rhinosinusitis without nasal
polyps (CRSsNP). This classification is referred to as
phenotype classification.
There is currently increasing evidence to suggest
that there are numerous endotypes of CRS, with differ-
ent pathophysiologies and different forms of inflam-
mation within the phenotypes CRSwNP and CRSsNP.
This is particularly true for CRSwNP, which affects ap-
proximately 1–4% of the general population [1].
Histologically, nasal polyps are pale gray, edema-
tous, sometimes also fibrous, stalked protrusions that
develop in the middle nasal passage, the ethmoid
bone, and the middle nasal turbinate [5]. For rea-
sons as yet unknown, the lower nasal turbinate does
not tend to form polyps [6–9]. Nasal polyps can be
divided into at least four groups according to his-
tological criteria [10–12]. At a frequency of 65–90%,
edematous, eosinophilic polyps are the most common
form of nasal polyps [9, 12]. Further differentiation of
CRSwNP phenotypes may help to develop new ther-
apeutic strategies that are tailored to the respective
classification.
However, the partially overlapping histological fea-
tures do not always permit precise classification into
a certain type. Against this background, there is also
a discussion about whether histological examinations
could be influenced by different preoperative medica-
tions [12]. Therefore, it is currently unclear how differ-
ing therapies for the clinical treatment of nasal polyps
can be determined on the basis of these classifica-
tions. For this reason, reliable and easy-to-determine
biomarkers beyond classical histology would be highly
desirable and could significantly improve diagnostics.
However, these are not available as yet [13].
All forms of CRS appear to be caused by inflam-
matory changes in the sinonasal mucosa. A Th2-
mediated inflammatory process is usually found in
CRSwNP, whereas both Th2- and Th1-mediated pro-
cesses are found in CRSsNP [1]. However, this sub-
division is an over-generalization and is by no means
found consistently, which is why the latest findings in
this regard are described in more detail below.
Immunology of nasal polyps
In recent years, the T cell subpopulations in chronic
sinusitis and nasal polyposis have been well charac-
terized and their biological function determined.
CD4+ T cells are able to differentiate into, e. g.,
T helper cells (Th)1, Th2, Th9, Th17, Th22, and fol-
licular T helper (TFH) effector cells [14, 15]. The
balance between these T helper subtypes is extremely
important for the physiology of the mucosal immune
system and can be altered by persistent inflamma-
tory processes. Eosinophilic, Th2-dominated cell
infiltration is usually seen in CRSwNP [1]. The in-
flammatory process is characterized by interleukin
(IL)-4-, IL-5- and IL-13-producing Th2 cells, as well
as eosinophilic cationic protein (ECP) and eotaxin-1/
-2/-3 [16, 17]. Each of these cyto- and chemokines
has specific functions. IL-4 is a mediator and modula-
tor of the immune and inflammatory response and is
mainly produced by Th2 cells. In addition, IL-4 is able
to promote the differentiation of CD4+ T cells into Th2
cells and at the same time inhibit interferon (IFN)-γ
production and Th1 response [18, 19]. It was shown
only recently that upregulation of IL-4 occurs in nasal
polyps, whereas IFN-γ expression is reduced, and that
IFN-γ levels do not differ significantly between nasal
polyps and control tissue [17, 20, 21]. IL-5 is the
most important eosinophilic activating cytokine and
promotes the survival of mature eosinophils in tissue
[22, 23]. IL-5 is upregulated in nasal polyps [24] and
plays an important role in the pathogenesis of nasal
polyps. ECP and eotaxin promote the attraction and
activation of eosinophils and are also upregulated in
nasal polyps [16, 17, 25].
IL-6 is a proinflammatory cytokine capable of in-
hibiting neutrophil recruitment [26–28] and was also
found to be upregulated in CRSwNP [29, 30]. How-
ever, the differing data on regulatory molecules of the
IL-6 signaling pathway do not answer the question
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of whether the IL-6 signaling pathway is part of the
pathogenesis of CRSwNP.
Keswani and colleagues [31], as well as Cho et al.
[32], found elevated expression of IL-32 in whole tis-
sue extracts from nasal polyps. IL-32 is also described
as a proinflammatory cytokine [33–38], which appears
to play a role in various inflammatory disorders such
as chronic obstructive pulmonary disease (COPD) and
atopic dermatitis [39, 40]. Nine different isoforms of
IL-32 are now known, although their functional dif-
ferences remain unclear [34, 41]. Further studies are
required to assess the role of IL-32 in nasal polyps in
patients with chronic rhinosinusitis.
IL-25 and IL-33 are other cytokines that are pro-
duced in sinonasal epithelial cells and which promote
Th2 inflammation in CRSwNP [42–44]. IL-25 is up-
regulated in nasal polyps and increases thymic stro-
mal lymphopoietin (TSLP)-induced Th2 cell expan-
sion [45, 46]. Increased expression of TSLP in the ep-
ithelium of patients with CRSwNP has already been
demonstrated [47–49]. This is an IL-7-like cytokine.
This effectively activates mast cells in combination
with IL-1 to produce in turn Th2 cytokines, includ-
ing IL-5 and IL-13 [50]. A study from Baltimore (MA,
USA) showed that the sinonasal epithelial cells of pa-
tients with untreated CRSwNP show increased basal
expression of IL-33 compared with sinonasal epithe-
lial cells in patients with CRSwNP following treatment
with methylprednisolone [51]. This increased expres-
sion of IL-33 in untreated polyps was confirmed by
another working group [52]. IL-33 is a chemoattrac-
tant for Th2 cells and promotes the production of Th2
cytokines such as IL-4, IL-5, and IL-13. Epithelial cells
of the respiratory tract are able to produce IL-33; its re-
ceptor is expressed by, e. g., eosinophils and Th2 lym-
phocytes [53]. IL-33 plays an important role in main-
taining Th2-mediated eosinophilic inflammation [54].
Thus, polymorphisms within the IL-33 receptor gene,
the interleukin-1 receptor-like 1 (IL1RL1) gene, corre-
late with CRS severity [55]. It is assumed that IL-25
and IL-33 are able to establish the link between ep-
ithelial cells and the Th2 response [42]; however, this
needs to be investigated further.
On the other hand, the cytokines IL-25, IL-33, and
TSLP have an effect on type 2 innate lymphoid cells
(ILC2) [56]. These are lymphocyte-like cells that do
not express any allergen-specific T cell receptors. ILCs
are considered to be counterparts of Th2 cells, since
both produce cytokines such as IL-5 and IL-13 [57],
meaning that ILC2 activated by IL-33 and IL-25 can in-
duce eosinophilic respiratory tract inflammation [58,
59]. ILC2 are abundant in nasal polyps and are asso-
ciated with an increased number of eosinophils in the
blood and tissue of patients with CRSwNP and a clini-
cally relevant worsening of total nasal symptom score
(TNSS) and asthma comorbidity [60, 61].
In addition to eotaxin-1/-2/-3, various chemokines,
such as CC motif chemokine ligand 5 (CCL5 or
RANTES), CXC motif chemokine ligand 8 (CXCL8
or IL-8), CCL23, CCL18, CXCL12 (stromal cell-derived
factor 1 α, SDF-1 α), and CXCL13 (B cell-attracting
chemokine 1, BCA-1), have been linked to the selec-
tive recruitment of inflammatory cells in the mucosa
in CRSwNP. RANTES was one of the first identified
chemokines found to be upregulated in nasal polyps
[62, 63]. RANTES is a member of the CC chemokine
family and a strong chemoattractant for eosinophils
and T-lymphocytes, but not for neutrophils, and is
primarily secreted by nasal epithelial cells [62, 64,
65]. RANTES is also expressed and secreted in nasal
polyps. Interestingly, nasal polyps with a high number
of eosinophils exhibit significantly increased RANTES
gene and protein expression. Consequently, increased
RANTES expression results in an increased number
of eosinophils in tissue. Therefore, RANTES likely
also plays an important role in the mobilization of
eosinophils in nasal polyps.
CXCL8 (IL-8), which attracts neutrophils and eosin-
ophils into the nasal mucosa, provided these have
been previously activated by IL-5, plays a further role
in nasal polyp inflammation [66]. IL-8, however, is
considered more of an unspecific marker for CRSwNP.
Although altered levels of IL-8 were identified in nasal
polyps [30, 66–69], upregulation does not correlate
significantly with the formation of nasal polyps [66].
Poposki and colleagues [70] were able to show
strong production of CCL23 in nasal polyps, which
was largely colocalized with ECP, indicating predomi-
nantly eosinophilic CCL23 production in nasal polyps.
CCL23 is a chemoattractant for monocytes, dendritic
cells, and lymphocytes, and it has been shown that
CCL23 induces endothelial cell migration via the CC
motif chemokine receptor CCR1, which is also up-
regulated in nasal polyps [70–73]. It has been shown
for Th2 cytokines such as IL-4 and IL-13 that these
induce CCL23 expression in monocytes [74].
In addition, significantly increased CCL18-mRNA
expression was found in nasal polyps and the inferior
tubinates [75]. M2 macrophages and mast cells were
identified in CRSwNP that express CCL18, which can
be induced by the Th2 cytokines IL4-, IL-13, and IL-10
[75]. Since the related receptor CCR8was only recently
identified, the role of CCL18 in the pathogenesis of
CRSwNP has not yet been investigated in detail [76].
However, this discovery will help clarify the role of
CLL18 in CRSwNP.
Both B cells and the antibody fractions IgA and IgE
were found to be elevated in patients with CRSwNP
[77, 78]. B cells express IgA, which triggers the de-
granulation of eosinophils and represents a possible
link to CRSwNP [77]. In this context, it was shown that
the chemokines CXCL12 (SDF-1 α) and CXCL13 (BCA-
1) are present at elevated levels in nasal polyps. Both
attract B cells. Furthermore, the receptors for SDF-
1 α (CXCR4 and CXCR7) and BCA-1 (CXCR5) are also
present at elevated levels [79]. Consequently, the ex-
pression of SDF-1 α and BCA-1 in nasal polyps could
be important for the recruitment and maintenance of
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Fig. 1 The immunological processes in nasal polyps.
CRSwNP can be divided into three different endotypes:
the T cell-/Th2 cytokine-based endotype, the B cell-/IgE-
based endotype, and the eosinophil-based endotype. This
gives rise to different treatment approaches in CRSwNP.
CRSwNP chronic rhinosinusitis with nasal polyps; CD clus-
ter of differentiation; IL interleukin; TSLP thymic stromal lym-
phopoietin; Th T-helper; ILC innate lymphoid cell; CXCL CXC
motif chemokine ligand; CXCR CXC motif chemokine re-
ceptor; Ig immunoglobulin; IFN interferon; CCR CC motif
chemokine receptor; CCL CC motif chemokine ligand
B cells. In addition, the increased IgA levels imply
an important role for B cells in the pathogenesis of
CRSwNP.
Immunological processes are complex and involve
a multitude of cell types and proteins. Fig. 1 shows
the immunological processes known in nasal polyps.
Phenotypes of CRS
For some time now, CRS has been divided into dif-
ferent entities. The likely simplest classification into
CRSsNP and CRSwNP is based on endoscopic or
rhinoscopic findings.
Comorbidities of CRS
Another traditional classification of CRS is based on
its association with other diseases, e. g., the comor-
bidity of CRSwNP with cystic fibrosis (CF), aspirin in-
tolerance syndrome (AIS) or NASID-Exacerbated Res-
piratory Disease (N-ERD), inhalation allergies, immu-
nodeficiency syndromes, allergic fungal sinusitis, We-
gener’s granulomatosis, and bronchial asthma [1].
With regard to CF, nasal polyps are present in ap-
proximately 40% of these patients [80]. These polyps
show a more neutrophilic inflammation pattern with
overexpression of IL-1 β, IL-8, IL-21, myeloperoxidase
(MPO), and IL-17-producing Th17 cells [17, 20, 81]. As
part of this, IL-1 β and IL-17 mediate T cell differenti-
ation towards a Th17 phenotype [82]. CF is caused by
a defect in the transport of chloride and bicarbonate
(cystic fibrosis transmembrane conductance regulator
protein, CFTR) [83, 84]. To diagnose CF, chloride sweat
tests (the sweat of CF patients contains more than
60mmol/l chloride, or in the case of newborns, over
90mmol/l chloride) and molecular genetic screening
methods, among others, are performed [83, 84].
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The prevalence of N-ERD among patients with
CRSwNP is approximately 16%, while, conversely,
up to 96% of N-ERD patients have nasal polyposis
[1, 9]; therefore, a direct pathophysiological link be-
tween N-ERD and nasal polyps has been discussed
for some time. The cytokine profile of nasal polyps
in N-ERD patients shows the typical components of
a Th2 disease, as well as eosinophilia and signifi-
cant upregulation of IL-4 and IL-5 [85]. In addition,
significantly increased CCL23 expression is seen in
nasal polyps in patients with N-ERD [70]. How-
ever, the most striking feature is the increased IFN-
γ-expression of eosinophils [85], which is typically
associated with Th1 inflammation. To verify the sus-
pected diagnosis of N-ERD, oral provocation testing is
considered the gold standard alongside bronchial and
nasal provocation tests [86–88]. Research is underway
into the development of reliable in vitro laboratory
techniques as a diagnostic alternative to provocation
testing [87–89]. All laboratory chemical tests to date
have been based on detecting the impaired arachi-
donic acid metabolism in this disease [87–90].
The influence of inhalation allergies on the patho-
genesis of nasal polyps is the subject of controversy
[1]. In particular, the high prevalence of allergic
diseases in the European population makes direct
correlations challenging [91]. A study by Peric´ and
colleagues in 2012 [92] investigated the influence of
allergies in patients with nasal polyps. This study
involving 30 patients—13 with allergies, 17 without
allergies—investigated the cytokine and chemokine
levels in nasal secretions. The concentrations of IL-
4, IL-5, IL-6, and tumor necrosis factor (TNF)-β were
significantly higher in allergic patients compared with
non-allergic patients. In addition, the number of
eosinophils in nasal polyps was significantly higher
in allergic patients compared with the non-allergic
group. Moreover, it has been shown that both IL-6
and the Th2 cytokines IL-4 and IL-5 are more strongly
expressed in patients with allergic rhinitis [93, 94].
Interestingly, IL-6 was more highly expressed in nasal
polyps in allergic individuals than in nasal polyps in
non-allergic individuals [92, 95], suggesting that IL-6
and the IL-6 signaling pathway could play a potential
role in CRSwNP in patients with inhalation allergies.
Furthermore, studies on the pathogenesis of nasal
polyps have not demonstrated a link to elevated TNF-
β as yet. Also known as lymphotoxin (LT), TNF-β is
produced by Th1 cells, in addition to IFN-γ and TNF-
α, and promotes cellular inflammation [96]. As such,
TNF-β may be a potential marker for allergic nasal
polyps alongside IL-6.
Immunodeficiencies on the humoral and cellular
levels have also been associated with CRSsNP and
CRSwNP [97–100]. Defects in the production or func-
tion of IgA and IgG immunoglobulins, cellular effects
at the B cell level, T cells, neutrophils/monocytes,
and complement defects play an important role here
[97–100].
The prevalence of allergic fungal rhinosinusitis
(AFRS) or eosinophilic fungal rhinosinusitis (EFRS) in
patients with nasal polyposis is about 9–12% [101, 102]
and shows Th2-mediated inflammation with varying
levels of Th2 cytokines [103]. AFRS-/EFRS-related
nasal polyps exhibit a significantly higher level of IgE
and IL-5. However, further investigations are needed
to assess the role of AFRS/EFRS in the pathogenesis
of CRSwNP, since the so-called “fungal hypothesis” as
the cause of CRSwNP can be considered disproved
[1].
Furthermore, specific forms of CRS have been
described in sarcoidosis, Wegener’s granulomatosis,
congenital or acquired disorders of mucociliary clear-
ance and/or ciliary activity, as well as Churg–Strauss
syndrome [1, 100, 104].
Bronchial asthma is particularly frequently asso-
ciated with CRSwNP: approximately 40% of patients
with CRSwNP also suffer from bronchial asthma [9];
conversely, around 7% of asthma patients have nasal
polyps [1]. However, the correlation between asthma
and CRSwNP is poorly understood as yet. In a 2013
study, nasal secretions from 40 patients with nasal
polyps (20 with and 20 without asthma) were inves-
tigated for cytokine expression [105]. IL-5, IL-6, and
IL-10 levels were significantly increased in asthmatic
patients with nasal polyps compared with non-asth-
matic patients with nasal polyps. However, it is not
possible to say with any certainty at present that this
alteration can be attributed to the correlation with
asthma. Another study by Nabavi and colleagues
[106] found no differences in the serum expression
of IL-4, IL-13, and IFN-γ between asthmatic pa-
tients with CRSwNP and non-asthmatic patients with
CRSwNP. However, increased IgE levels were found.
To date, IL-5 and IgE were identified as indicators for
patients with CRSwNP and additional asthma [107].
Only recently, Tomassen and colleagues were able
to show that there is a correlation between clinical
characteristics and inflammatory endotypes of CRS.
Results showed that patients with high IL-5 levels had
the highest prevalence of nasal polyps and asthma. In
contrast, patients with low IL-5 levels were primarily
classified as CRSsNP. Thus, the prevalence of asthma
increases significantly depending on this endotype
classification in patients with CRSwNP. IL-5 remains
the main factor determining the phenotype with nasal
polyps and asthma, thereby gaining in importance as
a therapeutic target [30].
Endotypes of CRS
Four distinct endotypes of CRSwNP, albeit it with
clearly overlapping characteristics, have been defined
in a classification scheme [108] in a current review
article on endotype-based subtyping of CRSwNP:
● T cell-/Th2 cytokine-based endotype
● Eosinophil-based endotype
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Fig. 2 The affect of various comorbidities of CRSwNP on
the inflammatory profile in nasal polyps: different comorbidi-
ties of CRSwNP affect the development of endotypes of nasal
polyps. As a result, the classic inflammatory profile in nasal
polyps shifts and gains additional specific markers. When
associated with cystic fibrosis, the inflammatory profile of
nasal polyps changes extensively. CRSwNP chronic rhinos-
inusitis with nasal polyps; CF cystic fibrosis; AFRS allergic
fungal rhinosinusitis; EFRS eosinophilic fungal rhinosinusitis;
NAScA non-asthmatic sinusitis with allergy; AScA asthmatic
sinusitis with allergy; ASsA asthmatic sinusitis without al-
lergy; N-ERD NASID-Exacerbated Respiratory Disease; IL in-
terleukin; Th T-helper;MPOmyeloperoxidase; Ig immunoglob-
ulin; TNF tumor necrosis factor; CCL CC motif chemokine li-
gand
● B cell-/IgE-based endotype
● Cysteinyl-based endotype
Endotypes of CRS with various comorbidities
The various comorbidities of CRSwNP affect endotype
expression and the associated inflammatory profile
of nasal polyps (Fig. 2). Therefore, the diagnosis of
comorbidities should be included in endotype clas-
sification. This requirement has not been taken into
consideration in previous publications on endotype
classification in CRSwNP and could represent an im-
portant step on the way to personalized medicine or
precision medicine in CRSwNP.
Novel treatment approaches based on endotype
classification
Endotype classification gives rise to a number of
novel treatment approaches in CRSwNP, e. g., the
use of biologics such as dupilumab (anti-IL-4/13),
mepolizumab (anti-IL-5), or omalizumab (anti-IgE)
[109, 110].
These newly emerging therapies are aimed at a spe-
cific pathophysiological signaling pathway. How-
ever, careful selection of the patient population is
required to successfully implement such endotype-
based treatment approaches. Positive treatment out-
comes have already been demonstrated in CRSwNP
with the above-mentioned monoclonal antibodies
against IgE, IL-5, and IL-4/13 [111].
To date, however, only a selected patient collec-
tive has benefited from these developments. More
precise endotype classification of patients could po-
tentially help to optimize treatments. A discussion
will be required, for example, as to whether treatment
directed against a specific endotype is sufficient for
certain patient populations or whether combination
therapy might be necessary.
With regard to possible applications in the routine
treatment of CRS patients, it is essential to mention
here that there are no approved preparations for the
indications CRS and CRSwNP. Therefore, treatment
performed outside clinical trials has usually been car-
ried out in patients receiving these substances for
other indications or as individual treatment attempts
in the form of off-label therapy.
Conclusion
CRS is a heterogeneous group of inflammatory disor-
ders of the nasal and paranasal sinus mucosa. In clin-
ical routine, the disorder continues to be subdivided
into CRSsNP and CRSwNP on the basis of phenologi-
cal characteristics.
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However, there is no doubt that there are multi-
factorial pathophysiologies for CRSwNP in particu-
lar. These different endotypes have different signaling
pathways, from the process of initiation of inflamma-
tion, its maintenance, and its chronification to tissue
alteration. In addition to the “classic” CRSwNP endo-
type of Th2-based and eosinophil-dominated inflam-
mation, there are other endotypes that suggest differ-
ent therapeutic approaches [111].
Hitherto, endotype classifications have neglected
the fact that disorders associated with CRSwNP may
point to the endotype and the typical inflammatory
pattern that ensues. These should therefore be in-
cluded in new classifications to be developed in the
future.
Against this background, topical nasal glucocorti-
costeroids will remain the basic treatment in CRS and
surgical approaches will continue to be indispensable.
However, the addition of endotype-based individu-
alized treatments with potential biologicals to these
“basic treatment options” could help to put into ef-
fect the principle of “personalized medicine” in CRS
in the future.
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